- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07246629
Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage
Prophylactic Use of Intrathecal Calcium Channel Antagonist Through Lumbar Drain in Patients With Subarachnoid Hemorrhage Due to Aneurysmal Rupture
The purpose of this study is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a triple-blinded, prospective, sham, randomized study. The purpose of this research is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms. Patients will be randomized to standard treatment of cerebral vasospasm with prophylactic administration of intrathecal nicardipine vs standard treatment alone. The medication used is FDA approved and will be used through an intra-thecal route through a lumbar drain which is indicated in patients with subarachnoid hemorrhage.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sajid Suriya, MD
- Phone Number: 847-723-2078
- Email: Sajid.suriya@aah.org
Study Locations
-
-
Illinois
-
Park Ridge, Illinois, United States, 60068
- Advocate Lutheran General Hospital
-
Contact:
- Sajid Suriya, MD
- Phone Number: 847-723-2078
- Email: Sajid.suriya@aah.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- Aneurysmal subarachnoid hemorrhage with Hunt and Hess score 3 or less
- Patient or legal authorized representative available to sign the informed consent form
- Pre-morbid modified Rankin scale of 0 or 1.
- Patients who have lumbar drain placed or planned for cerebrospinal fluid diversion per standard of care
- Patients who are able to be randomized within 72 hours from arrival with aneurysmal subarachnoid hemorrhage or within 24 hours from lumbar drain placement
Exclusion Criteria:
- Pregnant females
- Subarachnoid hemorrhage (SAH) with hunt and hess scale of >3
- SAH due to etiology other than aneurysmal rupture
- Any contraindications in patients receiving calcium channel antagonists like hypersensitivity to dihydropyridines
- Active central nerve infection (CNS) infection or high suspicion of CNS infection
- Hemodynamic instability preventing the use of Nicardipine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Standard of Care
standard treatment of cerebral vasospasm and sham injection of 10 mL preservative-free normal saline in luer-lock sterile syringe |
10 mL preservative-free normal saline in luer-lock sterile syringe every 24 hours from randomization through day 14 post-bleed or lumbar drain removal, whichever occurs first. |
|
Experimental: Standard of Care Plus Nicardipine
standard treatment of cerebral vasospasm with prophylactic administration of intrathecal nicardipine |
Nicardipine 4 mg will be diluted in preservative-free normal saline to 10 mL in luer-lock sterile syringe every 24 hours from randomization through day 14 post-bleed or lumbar drain removal, whichever occurs first. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Vasospasm
Time Frame: up to hospitalization day 21
|
The incidence of symptomatic clinical or radiographic vasospasm in patients treated with prophylactic administration of intrathecal nicardipine though lumbar drain |
up to hospitalization day 21
|
|
Incidence of Delayed Cerebral Ischemia
Time Frame: up to hospitalization day 21
|
The incidence of symptomatic clinical or radiographic delayed cerebral ischemia in patients treated with prophylactic administration of intrathecal nicardipine though lumbar drain |
up to hospitalization day 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Rankin Scale Score
Time Frame: month 6
|
The Modified Rankin Scale is a clinical tool used to assess the functional disability after a stroke. It is a six-point ordinal scale that measures the patient's ability to perform activities of daily living. Score Range: 0 no symptoms, 1 no significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, 6 dead. |
month 6
|
|
Incidence of Meningitis
Time Frame: up to hospitalization day 21
|
Incidence of meningitis as confirmed by clinical and laboratory findings |
up to hospitalization day 21
|
Collaborators and Investigators
Investigators
- Principal Investigator: Krishna Joshi, MD, Advocate Lutheran General Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Hemorrhage
- Intracranial Arterial Diseases
- Aneurysm
- Intracranial Hemorrhages
- Pathological Conditions, Signs and Symptoms
- Subarachnoid Hemorrhage
- Intracranial Aneurysm
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Pharmaceutical Preparations
- Crystalloid Solutions
- Isotonic Solutions
- Solutions
- Dihydropyridines
- Nicardipine
- Saline Solution
Other Study ID Numbers
- IRB00139639
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.